These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7768562)

  • 41. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
    Giulumian AD; Pollock DM; Clarke N; Fuchs LC
    Am J Physiol; 1998 Jun; 274(6):R1613-8. PubMed ID: 9608015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat.
    Roesler JM; McCafferty JP; DeMarinis RM; Matthews WD; Hieble JP
    J Pharmacol Exp Ther; 1986 Jan; 236(1):1-7. PubMed ID: 2867209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.
    Watts SW; Fink GD; Northcott CA; Galligan JJ
    Br J Pharmacol; 2002 Sep; 137(1):69-79. PubMed ID: 12183332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.
    Li L; Fink GD; Watts SW; Northcott CA; Galligan JJ; Pagano PJ; Chen AF
    Circulation; 2003 Feb; 107(7):1053-8. PubMed ID: 12600921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats.
    Watts SW; Fink GD
    Am J Physiol; 1999 Mar; 276(3):H944-52. PubMed ID: 10070078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tonic action of endothelin type B and dopamine D3 receptors in spontaneously hypertensive and deoxycorticosterone acetate-salt hypertensive rats: effects of intrarenally applied selective antagonists.
    Badzynska B; Baranowska I; Sadowski J
    J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endothelin ET(B) receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats.
    Hashimoto N; Kuro T; Fujita K; Azuma S; Matsumura Y
    Biol Pharm Bull; 1998 Aug; 21(8):800-4. PubMed ID: 9743245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Upregulation of endothelin B receptors in kidneys of DOCA-salt hypertensive rats.
    Pollock DM; Allcock GH; Krishnan A; Dayton BD; Pollock JS
    Am J Physiol Renal Physiol; 2000 Feb; 278(2):F279-86. PubMed ID: 10662732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Involvement of endothelin-1 in deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy.
    Matsumura Y; Fujita K; Miyazaki Y; Takaoka M; Morimoto S
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S456-8. PubMed ID: 8587444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective antagonism of endothelin ET(A) or ET(B) receptor in renal hemodynamics and function of deoxycorticosterone acetate-salt-induced hypertensive rats.
    Matsumura Y; Taira S; Kitano R; Hashimoto N; Kuro T
    Biol Pharm Bull; 1999 Aug; 22(8):858-62. PubMed ID: 10480326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.
    Nabokov A; Amann K; Wagner J; Gehlen F; Münter K; Ritz E
    Nephrol Dial Transplant; 1996 Mar; 11(3):514-20. PubMed ID: 8671823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
    Hilditch A; Hunt AA; Gardner CJ; Twissell DJ; Polley J; Travers A; Drew GM; Middlemiss D; Ross BC; Robertson MJ
    Br J Pharmacol; 1994 Jan; 111(1):137-44. PubMed ID: 8012689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats.
    Hocher B; Rohmeiss P; Zart R; Diekmann F; Vogt V; Metz D; Fakhury M; Gretz N; Bauer C; Koppenhagen K; Neumayer HH; Distler A
    Cardiovasc Res; 1996 Apr; 31(4):499-510. PubMed ID: 8689641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
    Larivière R; Sventek P; Thibault G; Schiffrin EL
    Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic treatment with anti-endothelin antibodies fails to modify the development of hypertension in stroke-prone spontaneously hypertensive rats and DOCA-salt hypertensive rats.
    Yasujima M; Kanazawa M; Yoshida K; Kohzuki M; Watanabe H; Hiwatari M; Sato T; Abe K; Hirata Y; Yoshinaga K
    Tohoku J Exp Med; 1993 Jan; 169(1):43-50. PubMed ID: 8211968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.
    Park JB; Schiffrin EL
    Am J Hypertens; 2002 Feb; 15(2 Pt 1):164-9. PubMed ID: 11863252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
    Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
    Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.